- Company
- More options for ankylosing spondylitis including Taltz
- by Feb 9, 2021 06:04am
- The interleukin 17A (IL-17A) inhibitor drugs are taking over the spotlight in the ankylosing spondylitis treatment market. Besides the first-in-class Cosentyx (secukinumab), Taltz (ixekizumab) was released to the South Korean market with its strong evidences. Some specialists predict the guideline, initially recommending the drug to be used
- Company
- What now for Vyndamax failing essential drug designation?
- by Eo, Yun-Ho Feb 8, 2021 06:08am
- A transthyretin amyloid cardiomyopathy (ATTR-CM) new drug Vyndamax (tafamidis) seems to be struggling to receive National Health Insurance (NHI) reimbursement in South Korea. A pharmaceutical industry source reported Pfizer’s new drug treating patients with ATTR-CM Vyndamax (tafamidis 61 mg) has failed to get a treatment-purpose essentia
- Company
- Oncaspar for acute lymphocytic leukemia was approved
- by Eo, Yun-Ho Feb 8, 2021 06:08am
- According to the related industry, Servier Korea's Oncaspar (Pegaspargase) was approved from the MFDS as a rare specialty medicine as a combination therapy with other anti-tumor drugs when treating Acute Lymphoblastic Leukemia (ALL) in children and adults under the age of 8 years. Oncaspar is a drug that dramatically reduces the frequency
- Company
- Sanofi disturbs distributors with first vaccine bidding
- by Feb 8, 2021 06:08am
- Sanofi Pasteur, a first pharmaceutical manufacturer to jump into the vaccine bidding market and stir up the pharmaceutical distributor industry, could not ink the final procurement agreement. The company dropped its agreement offer as it failed to meet the bidder qualification standards. A pharmaceutical distributor industry reported on
- Company
- What is the expert evaluation of the single dose COVID-19 va
- by Whang, byung-woo Feb 8, 2021 06:07am
- Johnson & Johnson's COVID-19 vaccine, which has the advantage of a single vaccination, has been evaluated as not as expected, revealing 66% of the preventive effect. Experts are suggesting that approval is expected as long as they exceed the minimum standards of the WHO, but the evidence should be supplemented. On the 29th, Johnson & Jo
- Company
- Elyson challenges patent of Entresto
- by Kim, Jin-Gu Feb 5, 2021 10:09am
- Novartis' heart failure treatment Entresto (Sacubitril / Valsartan) is expected to be challenged by domestic companies. Interest is focused on whether domestic companies can overcome Entresto's patents, in which a total of 4 patents are registered. According to the pharmaceutical industry on the 4th, Elyson recently filed a judgment agains
- Company
- Delstrigo seeks reimbursement to join the HIV drug market
- by Eo, Yun-Ho Feb 5, 2021 05:51am
- MSD’s HIV new drug Delstrigo has started the National Health Insurance (NHI) reimbursement application process. The pharmaceutical industry reported, MSD Korea has submitted an application for the NHI reimbursement on an once-daily fixed-dose combination tablet Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate) treating
- Company
- Viatris’ Korean subsidiary has changed the name to Viatris
- by Feb 4, 2021 10:22am
- The Korean corporate name of the global healthcare company Viatris group will be officially changed to Viatris Korea from the 1st. Viatris’ Korean subsidiary (CEO: He-young Lee) was launched in November 2020 by combining Upjohn, a business division of global Pfizer, and Mylan, a global healthcare company. As the procedure for changing th
- Company
- Eisai Parkinson’s disease drug Equifina listed and launched
- by Eo, Yun-Ho Feb 4, 2021 06:08am
- Eisai’s Parkinson’s disease treatment Equifina has been released to the South Korean market on Feb. 2 with the National Health Insurance (NHI) reimbursement. The Ministry of Health and Welfare (MOHW) notice issued on Jan. 29 granted the NHI benefit on Equfina (safinamide) as an adjuvant treatment to levodopa for idiopathic Parkinson’s
- Company
- Stomach ulcer drug rebamipide market makes over KRW 100 bln
- by An, Kyung-Jin Feb 3, 2021 06:10am
- The impurity contamination in ranitidine was discovered in 2019 has in turn expanded a gastritis treatment rebamipide market. Although the market was sluggish for a long time, rebamipide prescription surged and broke through the 100 billion won point last year. The impurity contamination incident impacted the entire stomach disorder drug market
